| Oct 7 |
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
|
| Sep 17 |
Equillium collaborates with Vivtex for oral formulation of autoimmune therapy
|
| Sep 10 |
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
|
| Aug 28 |
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
|
| Aug 11 |
Equillium Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 9 |
Equillium GAAP EPS of $0.01 beats by $0.16, revenue of $13.9M beats by $7.57M
|
| Aug 8 |
Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates
|
| Aug 8 |
Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights
|
| Aug 6 |
Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
|
| Jul 18 |
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
|
